Advanced Pancreatic Cancer

Advanced metastatic pancreatic adenocarcinoma (mPAC) is increasing in frequency, but is still associated with a poor prognosis, with a five-year survival rate less than 5% and median overall survival of 4-6 months… (read more)

Enroll in Study

Breast Cancer

Ovarian suppression is essential in patients with moderate to high risk, hormone -receptor-positive (HR+) disease. A common treatment for these patients is ovarian suppression in combination with hormone therapy… (read more)

Enroll in Study

Chemotherapy-Induced Myelosuppression

Myelosuppression, also known as bone marrow suppression, is where bone marrow activity is decreased resulting in a reduction in blood cell production. Chemotherapy-Induced Myelosuppression (CIM) is a serious chemotherapy side effect… (read more)

Enroll in Study

Diffuse Large B-Cell Lymphoma 

Diffuse Large B-Cell Lymphoma (DLBCL) is a type of non-Hodgkin lymphoma, which is a cancer of white blood cells that may present with an array of symptoms like fatigue, weight loss, and pain… (read more)

Enroll in Study

Efficacy of Cryotherapy Device with Oral Mucositis

Oral mucositis is a common adverse reaction of standard stomatotoxic chemotherapy regimens for the treatment of cancer. It starts 5 -10 days after chemotherapy begins and lasts 7-14 days… (read more)

Enroll in Study

Indolent Non-Hodgkin’s Lymphoma (iNHL)

Indolent Non-Hodgkin’s Lymphomas (iNHLs), including follicular lymphoma (FL) and marginal zone lymphoma (MZL), usually have a good prognosis, but are not curable with the therapeutic options that are currently available… (read more)

Enroll in Study

Malignant Myeloid Hematologic Neoplasms

Myelofibrosis

Myelofibrosis (MF) is myeloproliferative tumor (MPN), which can manifest as primary myelofibrosis (PMF) or secondary MF developed from other MPN… (read more)

Enroll in Study

Metastatic Breast Cancer

The Revive Research Institute brings innovation to today’s oncology development to help manage trial complexities and increase the quality of the data collected in clinical trials. Many of the clinical researches performed at Revive has resulted in treatment breakthroughs and…

Enroll in Study

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Revive Research Institute is invested in introducing cutting-edge technology and life-changing clinical trials to advance medicine and healthcare… (read more)

Enroll in Study

Metastatic Castration-Sensitive Prostate Cancer

Metastatic castration-sensitive prostate cancer (mCSPC) is a form of advanced prostate cancer that may still be responsive to hormone treatment, but is more sensitive… (read more)

Enroll in Study

Metastatic Colorectal Cancer  (mCRC)

with EGFR Inhibitor Induced Acneiform Lesions

Epidermal Growth Factor Receptor Inhibitors (EGFRi) are commonly used and have been found to be successful in treating several types of cancers, including colorectal cancers… (read more)

Enroll in Study

Mutant Solid Tumors

Revive Research Institute is bringing game-changer therapies. Our team of expert physicians is involved in clinical research trials to deliver superior treatment strategies. Solid tumors are conglomerated masses of cells that may be malignant or benign and they may involve organs like the brain…

Enroll in Study

Positive Oropharyngeal Cancer 

Next-generation therapies in oncology have shown immense promise in pre-clinical research. To translate this discovery into treatment, Revive Research Institute is involved in numerous oncology clinical trials…

Enroll in Study

Predicting Immunotherapy Efficacy

Biospecimen Collection Study

Checkpoint inhibitors are the standard treatment for multiple common cancers by blocking the activation of programmed cell death proteins (PD-1). Current diagnostics for predicting response to immunotherapy, using programmed cell death ligand… (read more)

Enroll in Study

Relapsed/Refractory Follicular Lymphoma

Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma (NHL), representing 20% to 30% of all of the other types. Relapse of FL within 24 months of chemoimmunotherapy is seen quite commonly in patients. We strive to bring a therapy to treat…

Enroll in Study

Relapsed/Refractory Follicular Non-Hodgkin’s Lymphoma 

At Revive Research Institute, we aim to apply novel approaches to oncology therapies and innovative trial designs, including supportive (medical devices) and therapeutic clinical trials. According to the American Cancer Society…

Enroll in Study

Relapsed/Refractory Myelofibrosis

Myelofibrosis (MF) is an uncommon type of bone marrow cancer that disrupts the body’s normal production of blood cells. It causes extensive scarring to bone marrow leading to severe complications… (read more)

Enroll in Study

Uncontrollable Pain In Advanced Cancer

Cancer, disease condition which binds the patient to use lifelong medications with no promising cure. Even with palliative care and optimal use of medications, many patients still suffer enormously as cancer spreads. Revive Research Institute joins hands with the brightest minds in Medicine…

Enroll in Study

Uterine Serous Carcinoma

Uterine Serous Carcinoma (USC) is an aggressive form of serous endometrial cancer that presents with severe vaginal bleeding, pain in the pelvic region, and decreased quality of life… (read more)

Enroll in Study